Lundbeck enters migraine race with $2B takeout of Alder
By Stephen Hansen, Associate Editor | Sep 16, 2019 | 3:47 PM GMT
Lundbeck will add a CGRP inhibitor to its neurology pipeline by buying Alder for just shy of $2 billion, but the Scandinavian pharma will be playing catch-up as eptinezumab will likely be fourth among drugs in its class.
On Monday the
Read the full 403 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD